<DOC>
	<DOCNO>NCT00054951</DOCNO>
	<brief_summary>MTC-DOX Doxorubicin DOX , chemotherapy drug , adsorb , make “ stick , ” magnetic bead ( MTCs ) . MTCs tiny , microscopic particle iron carbon . When DOX add MTCs , DOX attach carbon part MTCs . MTC-DOX direct deposited area tumor , think “ leak ” blood vessel wall . Once surround tissue , think Doxorubicin become “ free ” magnetic bead able act tumor cell . The iron component particle magnetic property make possible direct MTC-DOX specific tumor sit liver placing magnet body surface . It hop MTC-DOX use magnet may target chemotherapy directly liver tumor provide treatment patient liver cancer . Patients enrol study administer MTC-DOX hepatic artery catheter insert radiological guidance . During follow injection MTC-DOX , drug localize hepatic tumor site use external magnet . Dose may divide order localize MTC-DOX lesion . The MTC-DOX intrahepatic infusion repeat every three week tumor progression , complete remission , unacceptable toxicity , maximum six treatment cycle . The purpose Phase 1/2 study evaluate time disease progression follow administration MTC-DOX .</brief_summary>
	<brief_title>Safety Efficacy Doxorubicin Adsorbed Magnetic Beads</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients may enrol protocol follow inclusion criterion meet : Patient unresectable hepatocellular carcinoma diagnose CT scan meet criteria describe Section 23 . Total combined crosssectional area hepatic tumor determine CT scan 4 150 cm2 . The center tumor ( ) mass must less equal 14 cm anterior lateral abdominal wall determine crosssectional imaging baseline . This required optimal placement magnet . If one tumor mass present , tumor mass must meet criterion . Patient ambulatory Karnofsky performance status score great equal 60 estimate life expectancy great equal 3 month . Patient 18 80 year old . Patient judge investigator initiative mean compliant protocol within geographical proximity allow followup . Patient legal representative ability give inform write consent prior initiation therapy . If patient female childbearing potential , must negative bHCG prior receive treatment . Patient must agree use effective method contraception ( e.g. , birth control pill , condom , intrauterine device , diaphragm , Norplant , DepoProvera ) . Patients exclude enrollment follow apply : Patient history cancer hepatocellular ( exclude resect basal cell carcinoma ; curatively resect stage 1 less cervical cancer disease free 5 year ) . Patient prior radiation therapy within last 6 month chemotherapy within last 4 week . Patients diffuse hepatocellular carcinoma disease preclude delivery drug tumor via vessel feed tumor . Patient another active medical condition ( ) organ disease ( ) may either compromise patient safety interfere safety and/or outcome ( e.g. , survival ) evaluation study drug . While exclusion limit follow abnormality , follow laboratory abnormality present , patient exclude : WBC &lt; 3,500/uL Platelets &lt; 40,000/ul Hemoglobin &lt; 9.5 gm/dL Total bilirubin &gt; 2.5 mg/dL ALT AST &gt; equal 5 x upper limit normal Serum Creatinine &gt; 2.0 mg/dL INR &gt; equal 2.0 Patient cardiac dysfunction leave ventricular ejection fraction &lt; 40 % . Patient physician plan concomitant chemotherapy , radiation therapy , hormonal and/or biological treatment cancer include immunotherapy ( exclude megace , oral contraceptive post menopausal estrogen replacement therapy ) study . Patients indwell cardiac pacemaker , cerebral aneurysm clip , indwell device appliance could adversely affect use external magnet . Patients document evidence hemachromatosis hemosiderosis . Patients CT Ultrasound evidence main first branch portal vein invasion thrombosis . Prior orthotopic hepatic transplant . Patient receive previous treatment doxorubicin , idarubicin , and/or anthracyclines anthracenes . Patient know allergy doxorubicin , MTCDOX component . Patient treat investigational drug , investigational biologic , investigational therapeutic device within 30 day initiate study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>Hepatoma</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>